In Vivo Direct Reprogramming of Resident Glial Cells into Interneurons by Intracerebral Injection of Viral Vectors
June 17th, 2019
11.1K views
This protocol aims at generating directly reprogrammed interneurons in vivo, using an AAV-based viral system in the brain and a FLEX synapsin-driven GFP reporter, which allows for cell identification and further analysis in vivo.
Overview
This study presents a protocol to generate directly reprogrammed interneurons in vivo from resident glia using an AAV-based viral system. Targeting NG2-glia with a FLEX synapsin-driven GFP reporter allows for cell identification and analysis, particularly focusing on parvalbumin-positive interneurons with implications for psychiatric disorders.
Key Study Components
Area of Science
- Neuroscience
- Neurobiology
- Cell Reprogramming
Background
- Development of novel neurons from resident glial cells.
- Neurological conditions targeted through specific neuronal phenotypes.
- Utilization of AAV viral vectors for efficient gene delivery.
- Reprogrammed interneurons may provide insights into cell replacement therapies.
Purpose of Study
- To demonstrate in vivo conversion of glia into mature, subtype-specific interneurons.
- To investigate implications for psychiatric disorders via parvalbumin-positive interneurons.
- To establish a method for potential applications across various brain areas.
Methods Used
- In vivo reprogramming using AAV5 viral vectors in mouse models.
- Targeting of NG2-glia for generating specialized interneurons.
- Critical steps involve viral vector production, cell culture, and injection protocols.
- Evaluation of reprogrammed cells over a timeline of up to 12 weeks.
Main Results
- Successful conversion of resident glia into parvalbumin-positive interneurons.
- Demonstrated maturation and integration of reprogrammed neurons in vivo.
- Provided a methodology for future studies addressing neurological conditions.
Conclusions
- The study illustrates a viable approach for generating interneurons in vivo.
- Findings support future exploration into cell replacement therapies.
- Highlights the potential for studying neuronal mechanisms relevant to psychiatric disorders.
Frequently Asked Questions
What are the advantages of the AAV vector system?
AAV vectors offer specific targeting capabilities and efficient transduction, which enable precise reprogramming of glial cells within the brain.
How are the reprogrammed interneurons validated?
Validation is achieved through the expression of the GFP reporter, allowing for identification and analysis of the reprogrammed neurons in vivo.
What is the significance of generating parvalbumin-positive interneurons?
These interneurons have critical roles in modulating neuronal circuits and are linked to various psychiatric disorders, making their generation pivotal for research.
Can the method be applied to other brain regions?
Yes, the protocol is adaptable for targeting other neuronal phenotypes across different brain regions and circuits.
What are the limitations of this approach?
Potential limitations include the specificity of targeting and the efficiency of reprogramming, which may vary based on the physiological state of resident glia.
Executive Industry Relevance
In vivo reprogramming of resident glial cells into functional interneurons offers a novel approach to target validation in neuroscience drug discovery. This method enables mechanistic de-risking by generating disease-relevant neuronal subtypes directly in the brain, supporting predictive confidence in target engagement and circuit modulation. It provides a translational bridge for evaluating therapeutic hypotheses related to psychiatric and neurological disorders.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by generating subtype-specific interneurons in situ.
- Operational Value: Supports biological de-risking through direct conversion of resident glia into functionally validated neurons.
- Predictive Value: Facilitates portfolio triage by assessing target modulation effects on defined neuronal phenotypes.
Screening & Assay Development
- Scientific Value: Provides a reproducible biological system for assessing compound effects on neuronal maturation and electrophysiological function.
- Operational Value: Utilizes AAV-based reporter systems for standardized identification and longitudinal tracking of reprogrammed cells.
- Assay Readiness: Delivers quantitative outputs such as action potential firing patterns and synaptic connectivity for screening campaigns.
Translational & Preclinical Research
- Scientific Value: Establishes disease-relevant systems by producing parvalbumin-positive interneurons linked to psychiatric conditions.
- Operational Value: Enables continuity from discovery through preclinical validation via longitudinal electrophysiological and immunohistochemical assessment.
- Risk-Adjusted Advancement: Supports go/no-go decisions based on neuronal maturation, integration, and functional circuit incorporation over time.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through lead identification to preclinical evaluation by providing a stable, inducible neuronal model for mechanistic and phenotypic assessment.
- Discovery Biology: Supports hypothesis testing and pathway clarification by enabling controlled generation of defined interneuron subtypes in vivo.
- Screening: Offers assay readiness through GFP-labeled neurons and standardized electrophysiological readouts for compound screening.
- Analytics: Generates quantitative measurements including firing patterns, synaptic currents, and marker co-expression for comparative condition analysis.
- Translational Research: Connects to preclinical continuity via demonstrated maturation, synaptic integration, and functional validation over 12 weeks.
- Enterprise Reuse: Functions as a reusable platform for targeting multiple neuronal phenotypes across brain regions via adaptable AAV vector design.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through generation of authentic, subtype-specific interneurons with defined electrophysiological properties.
- Operational Value: Standardization and reproducibility via cre-dependent AAV vectors and GFP reporter systems for consistent cell identification.
- Strategic Value: Improved go/no-go decisions by reducing late-stage biological risk through early functional validation of neuronal targets.
- Portfolio Impact: Enables risk-adjusted prioritization based on target engagement in disease-relevant neuronal circuits.
Implementation Considerations
- Requires expertise in viral vector production, stereotaxic surgery, and electrophysiological recording techniques.
- Depends on ultracentrifugation, anion exchange filtration, and sterile filtration infrastructure for AAV purification and concentration.
- Necessitates cross-team standardization for surgical coordinates, postoperative care, and longitudinal tissue processing across discovery and preclinical teams.
- Involves adaptation considerations when targeting different glial populations or neuronal phenotypes beyond NG2-glia and parvalbumin interneurons.
- Practical limitations include variable reprogramming efficiency dependent on glial cell state and regional microenvironment, as noted in source material.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in glial reprogramming studies?
Null hypothesis testing ensures that observed neuronal maturation and functional integration are not due to random variation, supporting reliable target validation by confirming statistically significant reprogramming outcomes over time.
How does independent variable isolation fit the discovery pipeline in vivo reprogramming workflows?
Isolating the independent variable, such as specific transcription factor combinations, enables clear attribution of neuronal subtype generation to the reprogramming construct, supporting mechanistic de-risking in target validation.
What quantitative dependent variable measurements enable assessment of reprogrammed neuron functionality?
Quantitative measurements include action potential firing patterns, sodium and potassium current densities, and synaptic event frequency, which enable objective evaluation of neuronal maturation and circuit integration.
Why do replication requirements matter for cross-functional collaboration in glial reprogramming projects?
Replication across animals and time points ensures consistency in neuronal maturation and electrophysiological properties, enabling reliable data sharing between discovery, preclinical, and translational teams.
What statistical analysis capabilities are required before implementing in vivo reprogramming for target validation?
Capabilities include longitudinal data analysis, comparison of firing patterns across groups, and correlation of immunohistochemical markers with electrophysiological outputs to support robust target validation conclusions.
Chapters in this video
0:04
Title
1:16
AAV5 Viral Vector Production
3:41
AAV5 Viral Vector Purification
6:01
Injection of Reprogramming Factors into the Brain
8:34
Electrophysiological Recordings
10:33
Results: In Vivo Reprogrammed Neurons Are Functional and Show Maturation Over Time
11:44
Conclusion
